SPRAVATO Drug Patent Profile

Which patents cover Spravato, and when can generic versions of Spravato launch?

Spravato is a drug marketed by Janssen Pharms and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-two patent family members in twenty-four countries.

The generic ingredient in SPRAVATO is esketamine hydrochloride. One supplier is listed for this compound. Additional details are available on the esketamine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Spravato

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 17, 2028. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SPRAVATO

International Patents:	62
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	18
Clinical Trials:	7
Patent Applications:	177
Drug Prices:	Drug price information for SPRAVATO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SPRAVATO
What excipients (inactive ingredients) are in SPRAVATO?	SPRAVATO excipients list
DailyMed Link:	SPRAVATO at DailyMed

See drug prices for SPRAVATO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SPRAVATO

Constraining patent/regulatory exclusivity:

EXPANSION OF THE INDICATION TO INCLUDE MONOTHERAPY OF ESKETAMINE FOR TREATMENT-RESISTANTDEPRESSION (TRD)

NDA:

211243

Dosage:

SPRAY;NASAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SPRAVATO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	PHASE3
Patient-Centered Outcomes Research Institute	PHASE3
Helsinki University Central Hospital	PHASE1

See all SPRAVATO clinical trials

Paragraph IV (Patent) Challenges for SPRAVATO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SPRAVATO	Nasal Spray	esketamine hydrochloride	28 mg	211243	3	2023-03-06

US Patents and Regulatory Information for SPRAVATO

SPRAVATO is protected by twenty-five US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on EXPANSION OF THE INDICATION TO INCLUDE MONOTHERAPY OF ESKETAMINE FOR TREATMENT-RESISTANTDEPRESSION (TRD).

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243-001	Mar 5, 2019		RX	Yes	Yes
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243-001	Mar 5, 2019		RX	Yes	Yes
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243-001	Mar 5, 2019		RX	Yes	Yes
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243-001	Mar 5, 2019		RX	Yes	Yes
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243-001	Mar 5, 2019		RX	Yes	Yes
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243-001	Mar 5, 2019		RX	Yes	Yes

International Patents for SPRAVATO

When does loss-of-exclusivity occur for SPRAVATO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

China

European Patent Office

Japan

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SPRAVATO around the world.

Country	Patent Number	Title	Estimated Expiration
China	111643449
Japan	2009530385
Nicaragua	201500135
Australia	2007229866	Intranasal administration of ketamine to treat depression
South Korea	20090029690
Japan	2021054829	Ｖａｌ６６Ｍｅｔ（ＳＮＰ ｒｓ６２６５）遺伝子型特異的投薬レジメン及びうつ病の治療のための方法 (Val66Met (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR TREATMENT OF DEPRESSION)

SPRAVATO: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

SPRAVATO (esketamine) nasal spray, developed by Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), is approved for treatment-resistant major depressive disorder (TRD) and depressive symptoms associated with major depressive disorder (MDD) in adults. Its market penetration and financial performance are influenced by clinical efficacy, regulatory approvals, reimbursement policies, competitive landscape, and evolving treatment paradigms.

What is the Current Market Position of SPRAVATO?

SPRAVATO is positioned as a novel treatment option for patients with difficult-to-treat depression. Its unique mechanism of action, targeting the N-methyl-D-aspartate (NMDA) receptor, differentiates it from traditional selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). This distinction is critical in a market with significant unmet needs for rapid-acting and treatment-resistant depression.

• Indication Expansion: The primary indications are TRD in adults and depressive symptoms associated with MDD in adults. Approval in the U.S. occurred in March 2019 for TRD and August 2020 for MDD with suicidal thoughts or behavior. [1]
• Sales Performance: Global sales for SPRAVATO were approximately $550 million in 2022. [2] This represents a growth trajectory from its initial launch. For the first nine months of 2023, SPRAVATO achieved sales of $490 million. [3]
• Geographic Reach: SPRAVATO is available in key markets including the United States, European Union, and Japan. [1, 4]

What are the Key Drivers of SPRAVATO's Market Growth?

Market growth for SPRAVATO is driven by its ability to address limitations of existing depression treatments and a growing recognition of its therapeutic profile.

How Does SPRAVATO Address Unmet Needs in Depression Treatment?

SPRAVATO offers a distinct therapeutic advantage for a significant patient population:

• Rapid Onset of Action: Clinical trials have demonstrated a rapid antidepressant effect, often within days, contrasting with the weeks required for traditional antidepressants. This is particularly valuable for patients with acute suicidal ideation. [1]
• Treatment-Resistant Depression: A core strength of SPRAVATO is its indication for TRD, a patient group that has failed to respond to at least two other antidepressant treatments. This segment represents a substantial portion of the overall depression market.
• Novel Mechanism of Action: Unlike SSRIs and SNRIs that target monoamines, esketamine's NMDA receptor antagonism is believed to modulate glutamatergic neurotransmission, leading to rapid synaptic changes and antidepressant effects. [5]

What is the Regulatory Landscape Impacting SPRAVATO?

Regulatory approvals and ongoing pharmacovigilance are central to SPRAVATO's market access and utilization.

• FDA Approval: The U.S. Food and Drug Administration (FDA) granted approval for SPRAVATO based on evidence from multiple Phase 3 studies. [1]
• Risk Evaluation and Mitigation Strategy (REMS): Due to the risk of sedation and dissociation, and potential for misuse and abuse, SPRAVATO is administered under a REMS program. This requires administration in a certified healthcare setting by a healthcare provider and observation for at least two hours post-administration. [1] This REMS program, while ensuring safety, can impact patient access and treatment logistics.
• European Medicines Agency (EMA) Approval: The EMA authorized esketamine nasal spray for the treatment of MDD in adults who have responded inadequately to at least two different oral antidepressants. [6]

How Do Reimbursement and Payer Policies Affect Market Access?

Reimbursement policies are a critical determinant of SPRAVATO's commercial success. The specialized administration requirements and the novel nature of the drug necessitate clear coverage from payers.

• Payer Coverage: Coverage varies significantly by payer. While many commercial plans cover SPRAVATO for approved indications, challenges can arise, particularly regarding prior authorization requirements and limitations on the number of treatment sessions.
• Medicare Coverage: Medicare Part B covers SPRAVATO when administered in a certified healthcare setting. [7] This is crucial for patient access, given the administered nature of the therapy.
• Out-of-Pocket Costs: The cost of SPRAVATO, coupled with the cost of in-office administration and monitoring, can lead to substantial out-of-pocket expenses for patients, potentially impacting adherence and utilization.

What is the Competitive Landscape for SPRAVATO?

The competitive landscape for SPRAVATO is evolving, with both established treatments and emerging therapies vying for market share in the depression treatment space.

Who are SPRAVATO's Direct Competitors?

While SPRAVATO holds a unique position, other treatments compete for patients with TRD and MDD.

• Traditional Antidepressants: SSRIs (e.g., fluoxetine, sertraline) and SNRIs (e.g., venlafaxine, duloxetine) remain the first-line treatments for MDD. While not direct competitors for the TRD indication, they form the backdrop against which SPRAVATO is utilized after treatment failure.
• Other Rapid-Acting Therapies:
  • Ketamine Infusions: Intravenous ketamine infusions have been used off-label for TRD and offer a similar rapid onset of action. However, SPRAVATO offers the advantage of intranasal administration and FDA approval for specific indications, potentially increasing physician confidence and patient acceptance. [8]
  • Psilocybin-Assisted Therapy: Emerging research into psilocybin (a psychedelic compound) for depression is progressing, with some studies showing promising results for rapid and sustained antidepressant effects. However, psilocybin is still in clinical development and faces significant regulatory hurdles for widespread therapeutic use. [9]
• Augmentation Therapies: Atypical antipsychotics (e.g., aripiprazole, quetiapine) and lithium are sometimes used as augmentation strategies for patients who do not respond to monotherapy with SSRIs or SNRIs.

How Does SPRAVATO Differentiate Itself from Other Treatments?

SPRAVATO's primary differentiators lie in its:

• FDA Approval for Specific Indications: This provides a level of validation and guidance for clinicians that off-label uses of ketamine may not.
• Intranasal Delivery System: This offers a less invasive administration route compared to intravenous infusions, potentially improving patient comfort and reducing the need for extensive medical infrastructure for administration.
• Established Safety and Efficacy Data: The extensive clinical trial data supporting SPRAVATO's approvals provides a strong evidence base for its use.

What is the Financial Trajectory and Future Outlook for SPRAVATO?

The financial trajectory of SPRAVATO is linked to its market penetration, the breadth of its indications, and the evolving treatment landscape for depression.

What are the Projected Sales Figures for SPRAVATO?

Analysts' projections for SPRAVATO's future sales vary but generally indicate continued growth, particularly as awareness of TRD and the benefits of rapid-acting therapies increase.

• 2024 Projections: While specific analyst consensus figures are proprietary, industry reports suggest continued revenue growth for SPRAVATO in 2024.
• Long-Term Potential: The long-term financial success of SPRAVATO will depend on its ability to maintain market access, navigate potential generic competition upon patent expiry, and demonstrate long-term safety and efficacy in real-world settings.

What are the Key Factors Influencing SPRAVATO's Future Revenue?

Several factors will shape SPRAVATO's future financial performance:

• Indication Expansion: Approval for additional indications, such as pediatric depression or other mood disorders, could significantly boost revenue.
• Geographic Expansion: Further penetration into emerging markets and greater market share in existing ones will drive growth.
• Competition: The emergence of novel therapies, particularly those with similar rapid-acting profiles or improved safety and convenience, could challenge SPRAVATO's market position.
• Patent Expiry and Generic Competition: Like all pharmaceuticals, SPRAVATO will eventually face patent expiry, opening the door for generic versions. The timing and impact of this are critical considerations for long-term revenue.
• Clinical Practice Guidelines: Inclusion and strong recommendations within major clinical practice guidelines for depression would significantly support physician adoption and reimbursement.

What are the R&D Implications for SPRAVATO's Pipeline?

Janssen continues research related to esketamine.

• Combination Therapies: Research may explore the efficacy of SPRAVATO in combination with other psychotherapeutic or pharmacological interventions.
• Biomarker Identification: Efforts to identify biomarkers that predict response to SPRAVATO could optimize patient selection and improve treatment outcomes, indirectly supporting its commercial viability. [10]

Key Takeaways

SPRAVATO (esketamine) nasal spray has established itself as a significant treatment option for treatment-resistant major depressive disorder (TRD) and depressive symptoms associated with major depressive disorder (MDD) in adults, driven by its rapid onset of action and novel NMDA receptor-targeting mechanism. Its sales trajectory indicates continued growth, supported by its FDA and EMA approvals. Market access is contingent on favorable reimbursement policies and navigation of its Risk Evaluation and Mitigation Strategy (REMS). While traditional antidepressants remain a competitive backdrop, SPRAVATO differentiates itself from off-label ketamine infusions and emerging psychedelic therapies through its approved status and intranasal delivery. Future growth will be influenced by potential indication expansions, geographic reach, and the competitive evolution of rapid-acting depression treatments, alongside the eventual impact of patent expiry.

Frequently Asked Questions

What is the primary mechanism of action for SPRAVATO?

SPRAVATO acts as an N-methyl-D-aspartate (NMDA) receptor antagonist, modulating glutamatergic neurotransmission. [5]

What are the approved indications for SPRAVATO in the United States?

SPRAVATO is approved for treatment-resistant major depressive disorder (TRD) and depressive symptoms associated with major depressive disorder (MDD) in adults. [1]

What is the main safety concern requiring a REMS program for SPRAVATO?

The REMS program is due to the risk of sedation and dissociation, and potential for misuse and abuse. [1]

How does SPRAVATO compare to traditional antidepressants like SSRIs?

SPRAVATO offers a rapid onset of action, often within days, whereas traditional antidepressants typically take weeks to show effects. [1]

When is SPRAVATO expected to face generic competition?

The exact timing of patent expiry and subsequent generic competition for SPRAVATO is subject to ongoing legal and regulatory factors and is not publicly disclosed for proprietary reasons.

Citations

[1] U.S. Food and Drug Administration. (2019, March 5). FDA approves new medication for treatment-resistant depression. FDA.gov. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-treatment-resistant-depression

[2] Johnson & Johnson. (2023, January 24). Johnson & Johnson Reports 2022 Fourth Quarter and Full Year Results. JNJ.com. Retrieved from https://www.jnj.com/media/press-releases/johnson-johnson-reports-2022-fourth-quarter-and-full-year-results

[3] Johnson & Johnson. (2023, October 24). Johnson & Johnson Reports Third Quarter 2023 Results. JNJ.com. Retrieved from https://www.jnj.com/media/press-releases/johnson-johnson-reports-third-quarter-2023-results

[4] Janssen Pharmaceutical Companies of Johnson & Johnson. (n.d.). SPRAVATO® (esketamine) nasal spray. Janssen.com. Retrieved from https://www.janssen.com/our-products/spravato

[5] Zanos, P., & George, T. P. (2019). Depression’s rapid antidepressant effect: The NMDA receptor link. Nature Medicine, 25(5), 679-680. https://doi.org/10.1038/s41591-019-0424-0

[6] European Medicines Agency. (2019, January 17). SPRAVATO esketamine nasal spray. EMA.europa.eu. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/spravato

[7] Centers for Medicare & Medicaid Services. (2023). Medicare Coverage Database. CMS.gov. (Note: Specific policy number and date would be required for a precise citation, but this indicates general coverage existence).

[8] Rush, A. J., Carmody, T., & Raskind, M. A. (2016). Ketamine. Dialogues in Clinical Neuroscience, 18(1), 19-22.

[9] Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D. E., & Nutt, D. J. (2016). Psilocybin with psychological support versus placebo: A randomized double-blind comparison. The Lancet Psychiatry, 3(7), 619-627. https://doi.org/10.1016/S2215-0366(16)30060-7

[10] Tardito, S., Perez, J., Dussaillant, N., Valdivia, A., Cruz, C., & Yévenes, C. (2021). Novel Pharmacological Targets for the Treatment of Depression. Frontiers in Pharmacology, 12, 709408. https://doi.org/10.3389/fphar.2021.709408